Literature DB >> 11967658

Creutzfeldt-Jakob disease after Jannetta's operation with cadaveric dura mater graft: initial manifestations related to the grafted site.

Y Nishida, M Yamada, K Hara, T Tsunemi, M Yamawaki, R Shimokawa, R Okeda, T Tsutsumi, H Mizusawa.   

Abstract

Mesh:

Year:  2002        PMID: 11967658     DOI: 10.1007/s004150200055

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  5 in total

1.  Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK.

Authors:  C A Heath; R A Barker; T F G Esmonde; P Harvey; R Roberts; P Trend; M W Head; C Smith; J E Bell; J W Ironside; R G Will; R S G Knight
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04-20       Impact factor: 10.154

2.  Involvement of the peripheral nervous system in human prion diseases including dural graft associated Creutzfeldt-Jakob disease.

Authors:  C Ishida; S Okino; T Kitamoto; M Yamada
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

3.  MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease.

Authors:  B Meissner; K Kallenberg; P Sanchez-Juan; S Ramljak; A Krasnianski; U Heinemann; S Eigenbrod; E Gelpi; B Barsic; H A Kretzschmar; W J Schulz-Schaeffer; M Knauth; I Zerr
Journal:  J Neurol       Date:  2009-01-23       Impact factor: 4.849

4.  Clinical experience with a novel bovine collagen dura mater substitute.

Authors:  Bruno Silva Costa; George de Albuquerque Cavalcanti-Mendes; Marcelo Sartori de Abreu; Atos Alves de Sousa
Journal:  Asian J Neurosurg       Date:  2010-07

5.  Graft-related disease progression in dura mater graft-associated Creutzfeldt-Jakob disease: a cross-sectional study.

Authors:  Kenji Sakai; Tsuyoshi Hamaguchi; Moeko Noguchi-Shinohara; Ichiro Nozaki; Ichiro Takumi; Nobuo Sanjo; Yosikazu Nakamura; Tetsuyuki Kitamoto; Nobuhito Saito; Hidehiro Mizusawa; Masahito Yamada
Journal:  BMJ Open       Date:  2013-08-23       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.